Shuyun Wang

105 Jiefang Road
Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Targeting ILT4 to Improve Immunotherapy Efficacy in Solid Tumour: From Bench to Bedside.

Targeting ILT4 to Improve Immunotherapy Efficacy in Solid Tumour: From Bench to Bedside.

Journal: ImmunoTargets and therapy

Published: June 18, 2025

Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study.

Optimization of First-Line Treatment Options in HER2-Altered Lung Adenocarcinoma: A Real-World Study.

Journal: Cancer medicine

Published: March 14, 2025

Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment.

Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment.

Journal: Frontiers in immunology

Published: March 07, 2025

Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC.

Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC.

Journal: BMC pulmonary medicine

Published: March 01, 2025

Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score-matched analysis.

Prognostic impact of the timing of immunotherapy in first-line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score-matched analysis.

Journal: International journal of cancer

Published: September 28, 2024

Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer.

Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer.

Journal: BMC cancer

Published: August 16, 2024

Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma.

Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma.

Journal: Translational oncology

Published: August 11, 2024

Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.

Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.

Journal: International journal of cancer

Published: February 20, 2024

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study.

Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study.

Journal: Respiratory research

Published: December 18, 2023

ILT4 facilitates angiogenesis in non-small cell lung cancer.

ILT4 facilitates angiogenesis in non-small cell lung cancer.

Journal: Cancer science

Published: November 09, 2023

Efficacy of first-line treatment options beyond RET-TKIs in advanced RET-rearranged non-small cell lung cancer: A multi-center real-world study.

Efficacy of first-line treatment options beyond RET-TKIs in advanced RET-rearranged non-small cell lung cancer: A multi-center real-world study.

Journal: Cancer medicine

Published: September 27, 2023

ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.

ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer.

Journal: Journal of cell science

Published: January 15, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026